Advertisement

Journal of Endocrinological Investigation

, Volume 8, Issue 2, pp 135–141 | Cite as

3H-cyproterone acetate: binding characteristics to human uterine progestagen receptors

  • H. J. Grill
  • B. Manz
  • W. Elger
  • K. Pollow
Article

Abstract

The availability of tritium labeled cyproterone acetate (CPA) facilitated the systematic investigation of the binding characteristics of this compound for human uterine progesterone receptors (PgR). The binding parameters of 3H-CPA are compared to those of 3H-R5020 and 3H-progesterone. The rate constants of association (k1M-1sec-1) to PgR were 7.8 x 103 for 3H-R5020, 4.5 x 104 for 3H-progesterone and 4.0 x 104 for 3H-CPA. The rate constants of dissociation (k-1, sec-1) were 3.6 x 10-5 for 3H-R5020, 21.3 x 10-5 for 3H-progesterone and 17.8 x 10-5 for 3H-CPA. The Kd-values (M), as obtained by titration analysis and subsequent Scatchard plot analysis were 1.2 x 10-9 for 3H-R5020, 6.0 x 10-9 for 3H-progesterone and 5.2 x 10-9 for 3H-CPA. On sucrose density gradient analysis binding in the 3.5, 5 and 8 S area could be observed using 3H-R5020. For 3H-progesterone and 3H-CPA binding was exclusively found in the 5 S area. The specificity of the steroid binding site of PgR is identical for 3H-R5020 and 3H-CPA. The order of potency of binding for various competitors decreases identically for both radioactive ligands: R5020 < progesterone < R1881< CPA < dihydrotestosterone < dexamethasone < cyproterone < 15β-OH-cyproterone. CPA resembles progesterone very closely in its binding characteristics to human uterine PgR.

Key-words

Progesterone receptors cyproterone acetate H-CPA 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wiechert R., Steinbeck H., Elger W., Neumann F. Wirkungen und Struktur neuer antiandrogener Steroide. Arzneirh. Forsch. 17: 1103, 1967.Google Scholar
  2. 2.
    Bruchovsky N. Molekulare Wirkung von Androgenen unt Antiandrogenen. In: Hammerstein J., Lachnit-Fixon U., Neumann F., Plewig G. (Eds.), Androgenisierungserscheinungen bei der Frau. Excerpta Medica, Amsterdam, Oxford, Princeton, 1979, p. 7.Google Scholar
  3. 3.
    Mainwaring W.I.P. Modes of action of antiandrogens: a survey. In: Martini L, Motta M. (Eds.), Androgens and antiandrogens. Raven Press, New York, 1977, p. 151.Google Scholar
  4. 4.
    Neumann F., Elger W., Nishino Y., Steinbeck H. Probleme der Dosinfindung — Sexualhormone. Arzneim. Forsch. 27: 296, 1977.Google Scholar
  5. 5.
    Smith R.B., Walsh P.C., Goodwin W.E. Cyproterone acetate in the treatment of advanced carcinoma of the prostate. J. Urol. 110: 106, 1973.PubMedGoogle Scholar
  6. 6.
    Wein A.J., Murphy J.J. Experience in the treatment of prostatic carcinoma with cyproterone acetate. J. Urol. 109: 68, 1973.PubMedGoogle Scholar
  7. 7.
    Horn H.J. Administration of antiandrogens in hypersexuality and sexual deviations. In: Eichler O., Farah A., Herken H., Welch A.D. (Eds.), Handbook of experimental pharmacology. Springer-Verlag, Berlin, Heidelberg, New York, Band 35/2, 1974, p. 543.Google Scholar
  8. 8.
    Laschet U., Laschet L. Psychopharmacotherapy of sex offenders with cyproterone acetate. Pharmakopsychiatr. Neuropsychopharmakol. 4: 99, 1971.CrossRefGoogle Scholar
  9. 9.
    Neumann F., Diallo F.A., Hsan S.H., Schenck V., Traore I. The influence of pharmaceutical compounds on male fertility. Andrologia 8: 203, 1976.PubMedCrossRefGoogle Scholar
  10. 10.
    Roy S., Chatterjee S., Prasad M.R.N., Poddar A.K., Pandey D.C. Effects of cyproterone acetate on reproductive functions in normal human males. Contraception 14: 403, 1976.PubMedCrossRefGoogle Scholar
  11. 11.
    Beyer J., Demisch K., Wiegelmann W., Happ J., Kol-Imann F., Schöffling K. Cyproterone acetate in the treatment of infantile andro-genital syndrome with precocious puberty. Acta Endocrinol. (Kbh.) (Suppl.) 173: 169, 1973.Google Scholar
  12. 12.
    Rager K., Huenges R., Gupta D., Bierich J. The treatment of precocious puberty with cyproterone acetate. Acta Endocrinol. (Kbh.) 74: 399, 1973.Google Scholar
  13. 13.
    Wiechert R., Neumann F. Gestagene Wirksamkeit von 1 -Methyl- und 1, 2 -Methy-len-Steroiden. Arzneim. Forsch. 15: 244, 1965.Google Scholar
  14. 14.
    Neumann F. The physiological action of progesterone and the pharmacological effects of progesterone — a short review. Postgrad. Med. J. 54 (Suppl. 2): 11, 1978.Google Scholar
  15. 15.
    Plewig G., Luderschmidt S. Wirkung von Antiandrogen auf Talgdrüsen und Acne vulgaris. Tieruntersuchungen und Untersuchungen an Aknepatienten. In: Hammerstein J., Lachnit-Fixson V., Neumann F., Plewig G. (Eds.), Androgenisierungserscheinungen bei der Frau. Excerpta Medica, Amsterdam, Oxford, Princeton, 1979, p. 83.Google Scholar
  16. 16.
    Zaun H. Hirsutismus und androgentische Alopezie. Klinik und Diagnostik. In: Hammerstein J., Lachnit-Fixson V., Neumann F., Plewig G. (Eds.), Androgenisierungserscheinungen bei der Frau. Excerpta Medica, Amsterdam, Oxford, Princeton, 1979, p. 88.Google Scholar
  17. 17.
    Schenck V., Neumann F. Influence of antiandrogens on Sertoli cell function and intratesticular androgen transport. Intern. J. Androl. 7: 459, 1978.CrossRefGoogle Scholar
  18. 18.
    Neumann F., Elger W., Nishino Y., Steinbeck H. Probleme der Dosisfindung: Sexualhormone. Drug Res. 27: 296, 1977.Google Scholar
  19. 19.
    Viguier-Martinez M.C., Hocherau-DeReviers M.T. Comparative action of cyproterone and cyproterone acetate on pituitary and plasma gonadotropin levels, the male genital tract and spermatogenesis in the growing rat. Ann. Biol. Anim. Biochim. Biophys. 17: 1069, 1977.CrossRefGoogle Scholar
  20. 20.
    Beier S., Haase F., Kosub V., Dusterberg V., Elger W. The progestational activity of different gestagens used for human contraception in the beagle bitch. Contraception 20: 533, 1979.PubMedCrossRefGoogle Scholar
  21. 21.
    Elger W. Einflu β von Gestagenen auf Befruchtung, Eiernährung, Eitransport und Schwangerschaftsverlauf. In: Gunkmann K. (Ed.), Handbuch der experimentellen Pharmakologie. Springer-Verlag, Berlin, Heidelberg, New York, Band XXII, 1969, p. 132.Google Scholar
  22. 22.
    Scatchard D.G. The attraction of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51: 660, 1949.CrossRefGoogle Scholar
  23. 23.
    Waddell W.J. A simple ultraviolett spectrophotometric method for the determination of proteins. J. Lab. Clin. Med. 48: 311, 1956.PubMedGoogle Scholar
  24. 24.
    Price N.C., Dwek R.A. Principles and problems in physical chemistry for biochemists. Clarendon Press, Oxford, 1974.Google Scholar
  25. 25.
    Korenman S.G. Relation between estrogen inhibitory activity and binding to cytosol of rabbit and human uterus. Endocrinology 87: 1119, 1970.CrossRefGoogle Scholar
  26. 26.
    Neumann F., Schenck B. New antiandrogens and their mode of action. J. Reprod. Fertil. (Suppl.) 24: 129, 1976.Google Scholar
  27. 27.
    Philibert D., Ojasso T., Raynaud J.P. Properties of the cytoplasmic progestin-binding protein in the rabbit uterus. Endocrinology 101: 1850, 1977.PubMedCrossRefGoogle Scholar
  28. 28.
    Terenius L. Affinities of progestogen and estrogen receptors in rabbit uterus for synthetic progestogens. Steroids 23: 909, 1974.CrossRefGoogle Scholar
  29. 29.
    Wakeling A.E., Furr B.J.A., Glen A.T., Hughes L.R. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens. J. Steroid Biochem. 15: 355, 1981.PubMedCrossRefGoogle Scholar
  30. 30.
    Neumann F. Pharmakologie der Antiandrogene. In: Hammerstein J., Lachnit-Fixson V., Neumann F., Plewig G. (Eds.), Androgenisierungserscheinungen der Frau. Excerpta Medica, Amsterdam, Oxford, Princeton, 1979, p. 149.Google Scholar
  31. 31.
    Bhargava A.S., Soeger A., Gunzel P. Isolation and identification of 15β-hydroxy cyproterone acetate as a new metabolite in dog, monkey and man. Steroids 30: 407, 1977.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1985

Authors and Affiliations

  • H. J. Grill
    • 1
  • B. Manz
    • 1
  • W. Elger
    • 2
  • K. Pollow
    • 1
  1. 1.Abteilung für Experimentelle EndokrinologieJohannes Gutenberg Universität MainzMainzFRG
  2. 2.Schering AGBerlinFRG

Personalised recommendations